[go: up one dir, main page]

WO2002046471A3 - Methods and compositions for the identification, assessment and therapy of human cancers - Google Patents

Methods and compositions for the identification, assessment and therapy of human cancers Download PDF

Info

Publication number
WO2002046471A3
WO2002046471A3 PCT/US2001/041670 US0141670W WO0246471A3 WO 2002046471 A3 WO2002046471 A3 WO 2002046471A3 US 0141670 W US0141670 W US 0141670W WO 0246471 A3 WO0246471 A3 WO 0246471A3
Authority
WO
WIPO (PCT)
Prior art keywords
identification
assessment
therapy
compositions
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/041670
Other languages
French (fr)
Other versions
WO2002046471A2 (en
Inventor
Lajos Pusztai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
University of Texas at Austin
Original Assignee
University of Texas System
University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System, University of Texas at Austin filed Critical University of Texas System
Priority to AU2001291256A priority Critical patent/AU2001291256A1/en
Publication of WO2002046471A2 publication Critical patent/WO2002046471A2/en
Publication of WO2002046471A3 publication Critical patent/WO2002046471A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention is directed to the identification of markers that can be used to determine whether cancer cells are sensitive to a therapeutic agent. Nucleic acid arrays were used to determine the level of expression of approximately 6500 nucleic acid sequences (genes) found in certain cell lines treated with a chemotherapeutic agent. Expression analysis was used to identify genes associated with sensitivity to certain chemotherapeutic agents.
PCT/US2001/041670 2000-12-08 2001-08-09 Methods and compositions for the identification, assessment and therapy of human cancers Ceased WO2002046471A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001291256A AU2001291256A1 (en) 2000-12-08 2001-08-09 Methods and compositions for the identification, assessment and therapy of human cancers

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73385300A 2000-12-08 2000-12-08
US09/733,853 2000-12-08

Publications (2)

Publication Number Publication Date
WO2002046471A2 WO2002046471A2 (en) 2002-06-13
WO2002046471A3 true WO2002046471A3 (en) 2003-05-15

Family

ID=24949366

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/041670 Ceased WO2002046471A2 (en) 2000-12-08 2001-08-09 Methods and compositions for the identification, assessment and therapy of human cancers

Country Status (2)

Country Link
AU (1) AU2001291256A1 (en)
WO (1) WO2002046471A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004013355T2 (en) * 2003-10-15 2009-05-20 Roche Diagnostics Gmbh USE OF THE PROTEIN SPEE AS A MARKER FOR BREAST CANCER
US20070167478A1 (en) * 2003-12-22 2007-07-19 Anne Boulay Biomarkers for sensitivity of proliferative diseases to mtor inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5693465A (en) * 1994-09-20 1997-12-02 University Of Wales College Of Medicine Methods for predicting the behaviour of breast tumours
US5736326A (en) * 1987-05-05 1998-04-07 City Of Hope Method of detecting resistance to chemo therapeutic agents in cancer patients

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736326A (en) * 1987-05-05 1998-04-07 City Of Hope Method of detecting resistance to chemo therapeutic agents in cancer patients
US5693465A (en) * 1994-09-20 1997-12-02 University Of Wales College Of Medicine Methods for predicting the behaviour of breast tumours

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DUAN Z ET AL: "Discovery of differentially expressed genes associated with paclitaxel resistance using cDNA array technology: analysis of interleukin (IL) 6, IL-8, and monocyte chemotactic protein 1 in the paclitaxel-resistant phenotype", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 5, no. 11, November 1999 (1999-11-01), pages 3445 - 3453, XP002215670, ISSN: 1078-0432 *
GREGOIRE L ET AL: "DIFFERENTIAL EXPRESSION OF MRNAS IN A TAXOL-RESISTANT OVARIAN CANCER CELL LINE GROWTH IN THE PRESENCE OF TAXOL", PROCEEDINGS OF THE 89TH. ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. NEW ORLEANS, LA, MARCH 28 - APRIL 1, 1998, PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, PHILADELPHIA, PA: AACR, US, vol. 39, March 1998 (1998-03-01), pages 658,AN4479, XP001108999 *
LEICHMAN C G ET AL: "3223 - 3229", JOURNAL OF CLINICAL ONCOLOGY, PHILADELPHIA, PA, US, vol. 15, no. 10, October 1997 (1997-10-01), pages 3223 - 3229, XP001013038 *
PUSZTAI L ET AL: "TRANSCRIPTIONAL PROFILING OF NORMAL AND NEOPLASTIC BREAST EPITHELIAL CELLS AFTER EXPOSURE TO TAXOL", BREAST CANCER RESEARCH AND TREATMENT, NIJHOFF, BOSTON, US, vol. 57, no. 1, 1999, pages 138, XP002940579, ISSN: 0167-6806 *

Also Published As

Publication number Publication date
AU2001291256A1 (en) 2002-06-18
WO2002046471A2 (en) 2002-06-13

Similar Documents

Publication Publication Date Title
WO2001061050A3 (en) Methods and compositions for the identification, assessment, prevention and therapy of human cancers
WO2001079556A3 (en) Novel genes, compositions and methods for the identification, assessment, prevention, and therapy of human cancers
EP0732409A3 (en) Detection of human tumor progression and drug resistance
EA200501772A1 (en) METHODS OF MEASURING THE EXPRESSION OF GENES FROM FIXED AND PARULIN FABRIC SAMPLE
AU2001241541A1 (en) Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer
EP2270498A3 (en) Method for diagnosing non-small cell lung cancers
WO2002030268A3 (en) Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer
WO2004000094A3 (en) Predictive markers in cancer therapy
ZA200108258B (en) Methods of inducing cancer cell death and tumor regression.
ATE446373T1 (en) SEQUENCE-SPECIFIC DNA RECOMBINATION IN EUKARYOTIC CELLS
WO2001061048A3 (en) Methods and compositions for the identification, assessment, prevention and therapy of human cancers
WO2002081749A3 (en) Detection of aberrant dna methylation as marker for human cancer
WO2001041815A3 (en) Metastasis genes and uses thereof
WO2000018961A3 (en) Expression analysis of specific nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
WO2004009112A8 (en) Use of urease for inhibiting cancer cell growth
WO2002046471A3 (en) Methods and compositions for the identification, assessment and therapy of human cancers
WO2004013313A3 (en) Antisense nucleic acids
WO2003076610A3 (en) Variants of human kallikrein-2 and kallikrein-3 and uses thereof
WO2001038577A3 (en) Human transcriptomes
WO2001073430A3 (en) Identification, assessment, prevention and therapy of cancers
WO2001084156A3 (en) Identification, assessment, prevention, and therapy of human cancers
MXPA05011644A (en) CLAUDINSaCOE UNDEREXPRESSION AS MARKERS OF TUMOR METASTASIS.
Kleczkowska et al. Poly ADP-ribosylation in two L5178Y murine lymphoma sublines differentially sensitive to DNA-damaging agents
AU2001260309A1 (en) A process for determining the tumoricidal potential of a sample by the use of a nucleic acid which is downregulated in human tumor cells
WO2004044154A3 (en) Methods of identifying antineoplastic agents

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP